The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Quarterly Gardasil sales of $1.55 billion missed Wall Street's estimates of around $1.8 billion, which has been pared back nearly 20% since the issues in China were disclosed last summer.

Gardasil pause to China began this month Sales of Keytruda were over $7.8 billion in Q4, compared with analyst forecast of $7.4 billion Gardasil sales were $1.55 billion, compared with analyst ...

Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil revenue fell 17% to $1.55B due to lower China demand. Winrevair generated $200M Get ...

The increase is driven by growth in oncology and cardiovascular, partially offset by declines in diabetes, vaccines, immunology, and virology. Merck's blockbuster cancer immunotherapy Keytruda ...

(Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year ...

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare ...

Aside from RFK Jr.'s history of antivaccine rhetoric, the senators highlighted the nominee’s financial interest in litigation surrounding Merck’s HPV vaccine Gardasil. In an ethics agreement ...

The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February and going through at least mid-2025.

The pharma giant’s 2025 sales guidance reflects a decision to “temporarily pause” shipments of its HPV vaccine Gardasil to China, starting this month through “at least mid year” in ...